One form of amyloidosis, β2-microglobulin, is characteristic in renal dialysis patients. Amyloid is deposited in the skeleton and periosteal tissues and is a further manifestation of renal bone disease. About 200 mg of this protein are produced each day on cell surfaces, normally filtered by the glomeruli and catabolised in the tubuli. However, this low-molecular-weight protein does not filter well through dialysis membranes and as a consequence accumulates in tissues. After 10 or more years of dialysis, about 70% of patients are affected.